| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e581836258ec219600d55a2f55e6e912 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2011-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f97c75db34a2e4aced9ccef68e63be8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f0888db0d24e8d4a4de86fd5b03d6a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5a2f9ed683401ba7e2b1b093af8d083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f89de0e56580432b9ce573fef840669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0d0869ddf774a96552931bff519bf3c |
| publicationDate |
2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011171302-A1 |
| titleOfInvention |
Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs |
| abstract |
Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level C max of the memantine in a range of about 10-24 ng/mL during an average T max of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level C max of the AChEI in a range of about 12-38 ng/mL during an average T max of less than about 4 hours. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112618503-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3102186-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019388340-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110613715-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10894023-B2 |
| priorityDate |
2009-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |